NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$505.13

-8.94 (-1.74 %)

(As of 12/2/2020 12:00 AM ET)

Add

Compare

Today's Range

$503.81

Now: $505.13▼

$515.94

50-Day Range

$506.10

MA: $556.69▼

$607.98

52-Week Range

$328.13

Now: $505.13▼

$664.64

Volume760,404 shs

Average Volume1.12 million shs

Market Capitalization$53.90 billion

P/E Ratio19.56

Dividend YieldN/A

Beta0.51

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 13 buy ratings, 10 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $628.52, Regeneron Pharmaceuticals has a forecasted upside of 24.4% from its current price of $505.13.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Regeneron Pharmaceuticals has received 1,362 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Regeneron Pharmaceuticals has received 1,281 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Regeneron Pharmaceuticals has received 51.53% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote “Outperform” if you believe REGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,347,647.00 in company stock.
Percentage Held by Insiders
Only 11.84% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
85.89% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1 Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to grow by 16.73% in the coming year, from $28.16 to $32.87 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 19.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 20.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 19.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.52.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 1.80. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.14 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:REGN

Previous Symbol

CUSIP75886F10

CIK872589

Webwww.regeneron.com

Phone914-847-7000

Employees8,142

Debt

Debt-to-Equity Ratio0.08

Current Ratio2.12

Quick Ratio1.68

Price-To-Earnings

Trailing P/E Ratio19.56

Forward P/E Ratio17.94

P/E Growth1.8

Sales & Book Value

Annual Sales$7.86 billion

Price / Sales6.85

Cash Flow$20.98 per share

Price / Cash Flow24.08

Book Value$100.56 per share

Price / Book5.02

Profitability

EPS (Most Recent Fiscal Year)$21.47

Net Income$2.12 billion

Net Margins37.30%

Return on Equity26.71%

Return on Assets19.39%

Miscellaneous

Outstanding Shares106,706,000

Market Cap$53.90 billion

Next Earnings Date2/4/2021 (Estimated)

OptionableOptionable

$505.13

-8.94 (-1.74 %)

(As of 12/2/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock price been impacted by Coronavirus?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 8.7% and is now trading at $505.13.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 10 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported $8.36 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $9.52 by $1.16. The biopharmaceutical company earned $2.29 billion during the quarter, compared to analysts' expectations of $2.09 billion. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. The company's revenue for the quarter was up 31.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.67 EPS.
View Regeneron Pharmaceuticals' earnings history.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals announced that its board has initiated a share repurchase program on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

What price target have analysts set for REGN?

24 brokers have issued 1-year price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $429.00 to $800.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $628.52 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals.

Who are some of Regeneron Pharmaceuticals' key competitors?

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX), Ionis Pharmaceuticals (IONS) and Amicus Therapeutics (FOLD).
View all competitors.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 67, Pay $4.77M)
Dr. George D. Yancopoulos, Co-Founder, Pres & Chief Scientific Officer & Director (Age 60, Pay $3.98M)
Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 56, Pay $1.56M)
Dr. Andrew J. Murphy, Exec. VP of Research (Age 62, Pay $1.29M)
Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 47, Pay $1.46M)
Ms. Patrice Gilooly, Sr. VP of Quality Assurance & Operations
Mr. Gerald Underwood, Sr. VP of Technical Operations
Justin Holko, VP of Investor Relations
Mr. Joseph J. LaRosa, Exec. VP, Gen. Counsel & Sec. (Age 61)
Ms. Beth F. Levine, Sr. VP, Associate Gen. Counsel & Chief Compliance Officer (Age 56)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.20%), State Street Corp (4.38%), Nuveen Asset Management LLC (1.53%), Sands Capital Management LLC (0.80%), California Public Employees Retirement System (0.78%) and UBS Asset Management Americas Inc. (0.56%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Nuveen Asset Management LLC, Polar Capital LLP, Polar Capital LLP, Sustainable Growth Advisers LP, DNB Asset Management AS, LSV Asset Management, and Neuberger Berman Group LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, AQR Capital Management LLC, Candriam Luxembourg S.C.A., Swiss National Bank, UBS Asset Management Americas Inc., Voloridge Investment Management LLC, KBC Group NV, and Wells Fargo & Company MN.
View insider buying and selling activity for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $505.13.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $53.90 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,142 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings